Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.

European journal of medical research - 28 Jun 2010

Reuter S, Braken P, Jensen B, Sierra-Aragon S, Oette M, Balduin M, Kaiser R, Häussinger D

Abstract excerpt

OBJECTIVE: Few data are available about the efficacy of maraviroc (MVC) during routine use. We characterized indications for MVC use and the efficacy of MVC in clinical practice. METHODS: Thirty-two patients treated with MVC at our institution between 2006 and 2009 were included. Genotypic (n +/- 31) and phenotypic (n +/- 13) tropism analysis was performed. We determined indications for MVC use, characteristics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCR5 Receptor Antagonists
Share to Cyclohexanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Gene Expression Regulation, Viral

Share to Salvage Therapy

Share to Triazoles

Share to Viral Tropism

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 20696631
DOI: 10.1186/2047-783x-15-6-231
PMCID: PMC3351991

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.PMID 20696631Read ↗

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.Semantic proximity Read ↗

Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.Semantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.Semantic proximity Read ↗

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.Semantic proximity Read ↗

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.Semantic proximity Read ↗

Determination of HIV tropism and its use in the clinical practice.Semantic proximity Read ↗

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.Semantic proximity Read ↗

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.Semantic proximity Read ↗

Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.Semantic proximity Read ↗

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.Semantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.